Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brachytherapy, Stent, and TACE for HCC with PVTT
NCT02971345Phase 3Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2017
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of iodine-125 in hepatocellular carcinoma (HCC) and Portal vein tumor thrombus (PVTT), sponsored by Zhongshan Hospital, Fudan University. Status: unknown.
02
Drugs
iodine-125
03
Conditions
hepatocellular carcinoma (HCC)Portal vein tumor thrombus (PVTT)
Beyond the preview
Go deeper on NCT02971345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02971345.